Latest news with #Ovid
NZ Herald
2 days ago
- Entertainment
- NZ Herald
Did Kylie Jenner get plastic surgery? She did, and she'll tell you exactly how
Recently Kylie Jenner posted the exact details of her breast augmentation, even naming the doctor who performed the surgery. Photo / Getty Images The paradigm shifts as women like Kylie Jenner invert the Pygmalion story. In Ovid's Pygmalion an artist creates an ivory sculpture of a woman so beautiful that he falls in love with it. He kisses his statue, adorns it with jewels and finery, and prays to Venus for a bride
Yahoo
05-06-2025
- Business
- Yahoo
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company's OV329 clinical development program. World-leading expert, Dr. Alexander Rotenberg will join company management to discuss the emerging use of a wide range of biomarkers for the study of anti-seizure medicines. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30 to 10:30 am ET and will be webcast simultaneously. Sophisticated imaging and radiological tools are increasingly enabling medicines developers to leverage biomarkers earlier in clinical development to identify signals of biological target engagement and pharmacodynamic activity. Discussion will focus on how these tools drive evidence informed approaches in drug development and provide insight into potential clinical outcomes. Ovid management will describe the exploratory biomarkers in use to measure its next-generation GABA-aminotransferase (GABA-AT) inhibitor program, OV329, which is anticipated to have a topline readout in Q3 2025. Keynote speaker: Leading pediatric neurologist and epileptologist Alexander Rotenberg, M.D., Ph.D. Professor of Neurology at Boston Children's Hospital and Harvard Medical School, and Director of the Epilepsy Monitoring Unit at Boston Children's Hospital, and the Experimental Neurophysiology Core at F.M. Kirby Center of Neurobiology Unfortunately, nearly 40 percent of people living with epilepsy continue to experience seizures despite existing medicines. OV329 is a next-generation GABA-AT inhibitor, that was rationally designed to work differently from current medicines and may offer a novel approach for patients with treatment-resistant seizures. OV329 seeks to endogenously deliver optimal levels of GABA to reduce seizures and provide a preferable safety and tolerability profile relative to the first-generation, GABA-AT inhibitor, vigabatrin. OV329 is currently completing a Phase 1 study that is evaluating its effects on multiple pharmacodynamic biomarkers, safety, tolerability, and pharmacokinetics. Interested in attending or participating remotely: To register, please visit: Registration Link A live webcast of the presentation can be accessed through the Events & Presentations section of Ovid's website at About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit Forward-Looking Statements This press release includes certain disclosures by Ovid that contain 'forward-looking statements' including, without limitation: statements regarding the expected timing of initiation, completion, and results and data of Ovid's clinical studies; the potential use and development of OV329, OV350, OV4071 and other compounds from Ovid's library of direct activators of KCC2; and other statements that are not historical fact. You can identify forward-looking statements because they contain words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'may,' 'plan,' 'potentially,' and 'will,' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid's ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its business strategy or unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption 'Risk Factors' in Ovid's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ('SEC'), and in subsequent and future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Media and Investor Relations:Victoria Fort vfort@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-04-2025
- Business
- Yahoo
Wolters Kluwer Empowers Medical Research in India with Ovid as part of One Nation One Subscription (ONOS)
A significant achievement for academic and research communities in India NEW DELHI, India, April 24, 2025--(BUSINESS WIRE)--Wolters Kluwer is pleased to announce it is collaborating with the Government of India as part of One Nation One Subscription (ONOS). This pivotal initiative is aimed at enhancing research accessibility and equity across the nation. Launched on January 1, 2025, as part of its first phase, ONOS is designed to bolster research capacities by granting nationwide access to international journal publications from 30 distinguished publishers. This initiative caters to over 6,500 government institutions, benefiting approximately 1.8 crore (18 million) students, faculty, and researchers from higher education institutions and central government research institutions. The program is approved for the 2025-2027 calendar years, fostering interdisciplinary research across the country. Commenting on this development, Ruchi Tushir, VP & General Manager, GGM India, at Wolters Kluwer, expressed, "We are thrilled to announce this collaboration with the Government of India. This agreement represents our joint commitment to enhancing access to high-quality academic and research resources across the country. By providing access to Ovid, we aim to empower researchers, educators, and students with the tools they need to drive innovation and excellence in their respective fields." A Ministry of Education spokesperson added, "The collaboration with Wolters Kluwer through their participation in the One Nation One Subscription (ONOS) initiative of the Government of India represents a significant advancement in enhancing academic research in India. Through ONOS, the widespread availability of top-tier international journals to Government Higher Education Institutions and R&D Institutions will enable students, faculty, and researchers to foster innovation and knowledge growth in diverse interdisciplinary and multidisciplinary areas, in line with the National Education Policy, 2020." Providing clinical, evidence-based content trusted across India The Ovid research platform provides a vast library of thousands of full-text journal articles, eBooks, database resources, and workflow tools in a single, integrated solution. Ovid is a globally recognized leader in providing customizable solutions of high-quality content fully integrated with best-in-class technology tools that enhance research, scholarship, and patient care. Learn more about Wolters Kluwer: About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram. View source version on Contacts Media Contact Apoorva SharmaExternal CommunicationsWolters Sign in to access your portfolio
Business Wire
24-04-2025
- Business
- Business Wire
Wolters Kluwer Empowers Medical Research in India with Ovid as part of One Nation One Subscription (ONOS)
NEW DELHI, India--(BUSINESS WIRE)-- Wolters Kluwer is pleased to announce it is collaborating with the Government of India as part of One Nation One Subscription (ONOS). This pivotal initiative is aimed at enhancing research accessibility and equity across the nation. Launched on January 1, 2025, as part of its first phase, ONOS is designed to bolster research capacities by granting nationwide access to international journal publications from 30 distinguished publishers. This initiative caters to over 6,500 government institutions, benefiting approximately 1.8 crore (18 million) students, faculty, and researchers from higher education institutions and central government research institutions. The program is approved for the 2025-2027 calendar years, fostering interdisciplinary research across the country. Commenting on this development, Ruchi Tushir, VP & General Manager, GGM India, at Wolters Kluwer, expressed, 'We are thrilled to announce this collaboration with the Government of India. This agreement represents our joint commitment to enhancing access to high-quality academic and research resources across the country. By providing access to Ovid, we aim to empower researchers, educators, and students with the tools they need to drive innovation and excellence in their respective fields.' A Ministry of Education spokesperson added, 'The collaboration with Wolters Kluwer through their participation in the One Nation One Subscription (ONOS) initiative of the Government of India represents a significant advancement in enhancing academic research in India. Through ONOS, the widespread availability of top-tier international journals to Government Higher Education Institutions and R&D Institutions will enable students, faculty, and researchers to foster innovation and knowledge growth in diverse interdisciplinary and multidisciplinary areas, in line with the National Education Policy, 2020.' Providing clinical, evidence-based content trusted across India The Ovid research platform provides a vast library of thousands of full-text journal articles, eBooks, database resources, and workflow tools in a single, integrated solution. Ovid is a globally recognized leader in providing customizable solutions of high-quality content fully integrated with best-in-class technology tools that enhance research, scholarship, and patient care. Learn more about Wolters Kluwer: About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram.
Time of India
22-04-2025
- Business
- Time of India
Govt adds Wolters Kluwer's medical literature platform to One Nation One Subscription
New Delhi: The Government of India has partnered with Wolters Kluwer to provide access to its Ovid research platform under the One Nation One Subscription (ONOS) program. The Ovid platform, owned by Wolters Kluwer, delivers a wide array of full-text journal articles, eBooks, databases, and workflow tools in one cohesive, integrated solution, according to an official release. It offers customisable, high-quality content integrated with advanced technology tools designed to enhance research, academic scholarship, and patient care. Commenting on the development, a spokesperson from the Ministry of Education said, 'The collaboration with Wolters Kluwer through their participation in the One Nation One Subscription (ONOS) initiative of the Government of India represents a significant advancement in enhancing academic research across the country.' 'By providing access to Ovid, we aim to empower researchers, educators, and students with the tools they need to drive innovation and excellence in their respective fields,' added Ruchi Tushir, VP & General Manager, GGM India, Wolters Kluwer.
